Differences in epidemiology, liver disease and treatment response among HCV genotypes

Hepatology Research

Volumn 29, Issue 3, 2004, Pages 129-135

  Hadziyannis, Stephanos J ^a,b   Koskinas, John S ^b  

^a HENRY DUNANT HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS PROTEIN;

DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG RESPONSE; FATTY LIVER; GENETIC VARIABILITY; GENOTYPE; GREECE; HEPATITIS C; HUMAN; IRELAND; LIPID METABOLISM; LIVER DISEASE; MIDDLE EAST; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOUTH ASIA; VIREMIA; VIRUS CELL INTERACTION; VIRUS RESISTANCE;

EID: 2942635076     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2004.02.011     Document Type: Review

References (95)

1. WHO, Hepatitis Fact Sheet 164.
2. Alter M.J. Margolis H.S. Krawczynski K. Judson F.N. Mares A. Alexander J. et al. The natural history of community acquired hepatitis C in the United States N. Engl. J. Med. 327 1992 1899-1905
3. Seeff L.B. Natural history of chronic hepatitis C Hepatology 36 2002 S35-S46
4. Simmonds P. Variability of hepatitis C virus Hepatology 21 1995 57-83
5. Bourliere M. Barberin J.M. Rotily M. et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users J. Viral Hepatol. 9 2002 62-70
6. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003;7:45-66.
7. Poynard T. Ratziou V. McHutchison J. Manns M. Goodman Z. Zeuzem S. et al. Effect of treatment with peginterferon or interferon alpha-2b and ribavirin on steatosis in patients infected with hepatitis C Hepatology 38 2003 75-85
8. Rubbia-Brandt L. Quadri R. Abid K. Giostra E. Male P.J. Mentha G. et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3 J. Hepatol. 33 2000 106-115
9. Adinolfi L.E. Utili R. Andreana A. Tripodi M.F. Rosario P. Mormone G. et al. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients Eur. J. Gastroenterol. Hepatol. 12 2000 299-304
10. Fried M. Shiffman M. Reddy K. Smith C. Marinos G. Goncales F. et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 347 2002 975-982
11. Manns M. McHutchison J. Gordon S. Rustgi V. Shiffman M. Reindollar R. et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958-965
12. Hadziyannis S, Chienquer H, Morgan T, Diago M, Jensen D, Sette JH, et al. Peginterferon alpha-2a (40kD) in combination with ribavirin(RBV): efficacy and safety results from a phase III, randomized, double-blind multicentre study examining effect of duration of treatment and RBV dose. Ann Intern Med 2004;140:346-355.
13. Simmonds P. Alberti A. Alter H.J. Bonino F. Bradely D.W. Brechot C. et al. A proposed system for the nomenclature of hepatitis C viral genotypes Hepatology 19 1994 1321-1324
14. Enomoto N. Takada A. Nakao T. Date T. There are two major types of hepatitis C virus in Japan Biochem. Biophys. Res. Commun. 170 1990 1021-1025
15. Mizokami M. Gojobori T. Ohba K.I. Ikeo K. Ge X.M. Ohno T. et al. Hepatitis C virus types 7, 8 and 9 should be classified as type 6 subtypes J. Hepatol. 24 1996 622-624
16. Kolykhalov A.A. Feinstone S.M. Rice C.M. Indentification of a highly conserved sequence element at the 3′ terminus of hepatitis C virus genome RNA J. Virol. 70 1996 3363-3371
17. Bukh J. Purcell R.H. Miller R.H. Sequence analysis of the 5′ noncoding region of hepatitis C virus Proc. Natl. Acad. Sci. U.S.A. 89 1992 4942-4946
18. Simmonds P. The origin and evolution of hepatitis viruses in humans J. Gen. Virol. 82 2001 693-697
19. Power J.P. Lawlor E. Davidson F. Yap P.L. Kenny-Walsh E. Whelton M.J. et al. Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin Lancet 344 1994 1166-1167
20. Power J.P. Lawlor E. Davidson F. Holmes E.C. Yap P.L. Simmonds P. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin Lancet 345 1995 1211-1213
21. Smith D.B. Pathirana S. Davidson F. Lawlor E. Power J. Yap P.L. et al. The origin of hepatitis C virus genotypes J. Gen. Virol. 78 1997 321-328
22. Simmonds P. Mellor J. Craxi A. Sanchez-Tapias J.M. Alberti A. Prieto J. et al. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients J. Hepatol. 24 1996a 517-524
23. Pawlotsky J.M. Tsakiris L. Roudot-Thoraval F. Pellet C. Stuyver L. Duval J. et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C J. Infect. Dis. 171 1995 1607-1610
24. Frank C. Mohamed M.K. Strickland G.T. Lavanchy D. Arthur R.R. Magder L.S. et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt Lancet 355 2000 887-891
25. Ross RS, Viazov S, Renzing-Kohler K, Roggendorf M. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J Med Virol 2000;60:122-5.
26. Dal Molin G. Ansaldi F. Biagi C. et al. Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy J. Med. Virol. 68 2002 352-356
27. Van Asten L. Verhaest I. Lamzira S. et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis J. Infect. Dis. 189 2004 292-302
28. Czaja A.J. Carpenter H.A. Santrach P.J. Moore S.B. Host- and disease-specific factors affecting steatosis in chronic hepatitis C J. Hepatol. 29 2 1998 198-206
29. Hwang S.J. Luo J.C. Chu C.W. Lai C.R. Lu C.L. Tsay S.H. et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation J. Gastroenterol. Hepatol. 16 2001 190-195
30. Adinolfi L.E. Gambardella M. Andreana A. Tripodi M.F. Utili R. Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity Hepatology 33 2001 135-136
31. Hourigan L.F. Macdonald G.A. Purdie D. Whitehall V.H. Shorthouse C. Clouston A. et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis Hepatology 29 1999 1215-1219
32. Barba G. Harper F. Harada T. Kohara M. Goulinet S. Matsuura T. et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets Proc. Natl. Acad. Sci. U.S.A. 94 1997 1200-1205
33. Shi S.T. Polyak S.J. Tu H. Taylor D.R. Gretch D.R. Lai M.M. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins Virology 292 2002 198-210
34. Serfaty L. Andreani T. Giral P. Carbonell N. Chazouilleres O. Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C J. Hepatol. 34 2001 428-434
35. Hofer H. Bankl H.C. Wrba F. Steindl-Munda P. Peck-Radoasvljevic M. Osterreicher C. et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a Am. J. Gastroenterol. 93 2002 2880-2885
36. Moriya K. Yotsuyanagi H. Shintani Y. Fujie H. Ishibasi K. Matsura Y. et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice J. Gen. Virol. 78 1997 1527-1531
37. Perlemuter G. Sabile A. Letteron P. Vona G. Topilco A. Chretien Y. et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral related steatosis FASEB J. 16 2002 185-194
38. Okuda M. Li K. Beard M.R. Showalter L.A. Scholle F. Lemon S.M. et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein Gastroenterology 122 2002 366-375
39. Abid K, Rossi C, Latorre P, Rubbia-Brandt I, Hadengue A, Negro F. The core protein of HCV genotype 3a, 3b and 1a induces lipid accumulation in Huh7 cells. In: Proceedings of the Nineth International Meeting on HCV and Related Viruses 2002;A143.
40. Fujie H. Yotsuyanagi H. Moriya K. Shintani Y. Tsutsumi T. Takayama T. et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis J. Med. Virol. 59 1999 141-145
41. Mason A.L. Lau J.Y. Hoang N. Qian K. Alexander G.J. Xu L. et al. Association of diabetes mellitus and chronic hepatitis C virus infection Hepatology 29 1999 328-333
42. Ong J.P. Younossi Z.M. Speer C. Olano A. Gramlich T. Boparai N. Chronic hepatitis C and superimposed non-alcoholic fatty liver disease Liver 21 2001 266-271
43. Peters M.G. Terrault N. Alcohol use and hepatitis C Hepatology 36 2002 S220-S225
44. Roffi L. Ricci A. Ogliari C. Scaleri A. Minola E. Colleredo G. et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients J. Hepatol. 29 1998 701-706
45. Poynard T. Ratziu V. Charlotte F. Goodman Z. McHutchison J. Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C J. Hepatol. 34 2001 764-767
46. Kobayashi M. Tanaka E. Sodeyama T. Urushihara A. Matsumoto A. Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses Hepatology 23 1996 695-699
47. Poynard T. Ratsiu V. Charlotte F. Goodman Z. McHutchison J. Albrecht J. and Rates risk factors of liver fibrosis progression in patients with chronic hepatitis C J. Hepatol. 34 5 2001 730-739
48. Westin J. Nordlinder H. Lagging M. Norkrans G. Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients J. Hepatol. 37 2002 837-842
49. Bjoro K. Bell H. Hellum K.B. Skaug K. Raknerud N. Sandvei P. et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study Scand. J. Gastroenterol. 37 2002 226-232
50. Akuta N. Suzuki F. Tsubota A. Suzuki Y. Someya T. Kobayashi M. et al. Efficacy of interferon monotherapy to 394 consecutive näve cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartire interaction of viral, host and interferon treatment-related factors J. Hepatol. 37 2002 831-836
51. Zeuzem S, Hullcrantz R, Bourllere M, Gooser T, Marcellin P, Sanchez-Tapias J, et al. Peg-interferon alpha-2b 1.5μg/kg plus ribavirin 800-1400mg/day for 24 weeks in patients with HCV 2 or 3. Hepatology 2003;A347 (AASLD).
52. Esmat GH, Abouzied A, Abdel-Hamid M, Mohamed MK, Zalata K, Raziky MSE, et al. Results of a randomized clinical trial of genotype 4 infected subjects when treated with standard or pegylated interferon alpha-2b in combination with ribavirin. Hepatology 2003;A324 (AASLD).
53. Thakeb FIA, Omar MM, Bilharz T, Awady M, Isshak SY. Randomized controlled trial of peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus genotype 4 among Egyptian patients. Hepatology 2003;A252 (AASLD).
54. Hui C.K. Yuen M.F. Sablon E. Chan A.O. Wong B.C. Lai C.L. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1 J. Infect. Dis. 187 2003 1071-1074
55. Fukuda R.N. Ishimura Y. Kushiyama N. Moriyama S. Ishihara S. Nagasawa S. et al. Effectiveness of interferon alpha therapy in chronic hepatitis C is associated with the amount of interferon alpha receptor mRNA in the liver J. Hepatol. 26 1997 455
56. Poynard T. Leroy V. Cohard M. Thevenot T. Mathurin P. Opolon P. et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: effect of dose and duration Hepatology 24 1996 778-789
57. Tong M.J. Blatt L.M. McHutchison J.G. Co R.L. Conrad A. Prediction of response during interferon alpha 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison Hepatology 26 1997 1640-1645
58. Reddy K.R. Hoofnagle J.H. Tong M.J. et al. Racial differences in responses to therapy with interferon in chronic hepatitis C Hepatology 30 1999 787-793
59. Hu K.Q. Vierling J.M. Redeker A.G. Viral, host and interferon related factors modulating the effect of interferon therapy for hepatitis C virus infection J. Viral Hepatol. 8 2001 1
60. Olynyk J.K. Reddy K.R. Di Bisceglie A.M. Jeffers L.J. Parker J.L. Radick E.R. et al. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C Gastroenterology 108 1995 1104
61. Zeuzem S. Schmidt J.M. Lee J.H. et al. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo Hepatology 23 1996 366-371
62. Zeuzem S. Schmidt J.M. Lee J.H. et al. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover Hepatology 28 1998 245-252
63. Lam N.P. Neumann A.U. Gretch D.R. Wiley T.E. Perelson A.S. Layden T.J. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa Hepatology 26 1997 226-231
64. Neumann A.U. Lam N.P. Dahari H. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy Science 282 1998 103-107
65. Neumann A.U. Lam N.P. Dahari H. Davidian M. Wiley T.E. Mika B.P. et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus J. Infect. Dis. 182 2000 28-35
66. Zeuzem S, Pawlotsky JM, Hagai E, Wagner M, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing standard versus dynamically individualized treatment in patients with chronic hepatitis C (DITTO-HCV Project). Hepatology 2003;A317 (AASLD).
67. Enomoto N. Sakuma I. Asahina Y. et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A gene J. Clin. Invest. 96 1995 224-230
68. Enomoto N. Sakuma I. Asahina Y. et al. Mutations in the nonstructural proteins 5A and response to interferon in patients with chronic hepatitis C virus 1b infection N. Engl. J. Med. 334 1996 77-81
69. Gale Jr. M.J. Korth M.J. Tang N.M. et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5a protein Virology 230 1997 217-227
70. Murakami T. Enomoto N. Kurosaki M. Izumi N. Marumo F. Sato C. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection Hepatology 30 1999 1045-1053
71. Kato N. Lan K.H. Ono-Nita S.K. et al. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator J. Virol. 71 1997 8856-8859
72. Fukuma T. Enomot N. Marumo F. Sato C. The mutations in the interferon sensitivity determining region of hepatitis C virus and the transcriptional activity of NS5A protein Hepatology 28 1998 1147-1153
73. Zeuzem S. Lee J.H. Roth W.K. Mutations in the nonstructural 5a gene of European hepatitis C virus isolated and response to interferon alfa Hepatology 25 1997 740-744
74. Pawlotsky J.M. Germanidis G. Neumann A.U. Pellerin M. Frainais P.O. Dhumeaux D. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A quasispecies mutations J. Virol. 72 1998 2795-2805
75. Khorsi H. Castelain S. Wyseur A. et al. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients J. Hepatol. 27 1997 72-77
76. Tan S.L. Nako H. He Y. Vijaysri S. Neddermann P. Jacobs B.L. et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling Proc. Natl. Acad. Sci. U.S.A. 96 1999 5533
77. Taylor D.R. Shi S.T. Romano P.R. Berber G.N. Lai M.M.C. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein Science 285 1999 107-110
78. Saito T. Ito T. Ishiko H. Yonaha M. Morikawa K. Miyokawa A. et al. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotype 2a and 2b Am. J. Gastroenterol. 2003 2003 1377-1383
79. Yoshioka K. Aiyama T. Okumura A. et al. Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a J. Infect. Dis. 175 1997 505-510
80. Hattori M. Yoshioka K. Aiyama T. et al. Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: relation to viral loads and response to interferon Hepatology 27 1998 1703-1710
81. Mondelli M.U. Cerino A. Lisa A. et al. Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation Hepatology 30 1999 537-545
82. Brambilla S. Bellati G. Asti M. et al. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease Hepatology 27 1998 1678-1686
83. Missale G. Cariani E. Lamonaca V. et al. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b and genotype 2c infected patients Hepatology 26 1997 792-797
84. Negro F. Krawczynski K. Quadri R. et al. Detection of genomic- and minus-stand of HCV RNA in the liver of chronic HCV patients by strand specific semiquantitative RT-PCR Hepatology 29 1999 536-542
85. Gane E.J. Naoumov N.V. Qian K.P. Mondelli M.U. Maertens G. Portmann B.C. et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation Gastroenterology 110 1996 167-177
86. Feray C. Gigou M. Samuel D. Paradis V. Mishiro S. Maertens G. et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation Gastroenterology 108 1995 1088-1096
87. Feray C. Caccamo L. Alexander G.J. Ducot B. Gugenheim J. Casanovas T. et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHER) Group Gastroenterology 117 1999 619-625
88. Pageaux G.P. Ducos J. Mondain A.M. Castes V. Picot M.C. Perrigault P.F. et al. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection Liver Transpl. Surg. 3 1997 501-505
89. Di Martino V. Brenot C. Samuel D. Saurini F. Paradis V. Reynes M. et al. Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on FAS-mediated apoptosis after liver transplantation for hepatitis C Transplantation 70 2000 1390-1396
90. Berg T. Hopf U. Bechstein W.O. Muller A.R. Fukumoto T. Neuhaus R. et al. Pretransplant virological markers hepatitis C virus genotype and viremia level are not helpful in predicting individual outcome after orthotopic liver transplantation Transplantation 66 1998 225-228
91. Gayowski T. Singh N. Marina I.R. Vargas H. Wagener M. Wannstedt C. Hepatitis C virus genotypes in liver transplant recipients: impact on post-transplant recurrence, infections, response to interferon-alpha therapy and outcome Transplantation 64 1997 422-426
92. Vargas H.E. Laskus T. Wang L.F. Radkowski M. Poutous A. Lee R. et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation Liver Transpl. Surg. 4 1998 22-27
93. Zhou S. Terrault N.A. Ferrell L. Hahn J.A. Lau J.Y. Simmonds F. et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia Hepatology 24 1996 1041-1046
94. Streekumar R. Gonzalez-Koch A. Maor-Kendler Y. Batts K. Moreno-Luna L. Poterucha J. et al. Early identification of recipients with progressive histologic reccurence of hepatitis C after liver transplantation Hepatology 32 2000 1125-1130
95. Pessoa M.G. Bzowej N. Berenguer M. Phung Y. Kim M. Ferrell L. et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation Hepatology 30 1999 1513-1520